Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.

This Pipeline Selector report covers  Ambrisentan

Ambrisentan  indications:  Treatment of pulmonary arterial hypertension
Ambrisentan  innovator: Gilead (Letairis); Glaxosmithkline (Volibris)

Examples of information found in this online report include:

• Includes key patent publications for 44 countries  (see list below)
• Contains SPC protection for every EU state plus patent term extensions in other countries
• Data exclusivity calculated on a country by country basis
• Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
• DMF & Paragraph IV filings
• Litigation alerts
• Marketing authorisation holders in selected territories
• Patent risk analysis via graphical display of data from patent filings
• Hyper-linking to crucial patent documents and national registries enabling data verification

The 'Key Patent Indicator' enables easy identification of key patent, SPC and data protection expiry information covering 44 countries, including extension details (SPC and national law) for 30 European countries, Australia, Israel, Japan and the USA.  (also available with 44 country coverage):

Pipeline Selector 44 Country Coverage:

Country   Region  Extensions
Australia  Asia-Pacific S70
Canada   Americas N/A
USA   Americas S156
Germany   Western Europe SPC
Great Britain  Western Europe SPCS
France   Western Europe NAT/SPC
Spain   Western Europe SPC
South Africa   Africa   N/A
China    Asia-Pacific  N/A
Japan   Asia-Pacific S67
New Zealand   Asia-Pacific  N/A
Bosnia & Herzegovina    Balkan   N/A
Bulgaria    Balkan   SPC
Croatia    Balkan   N/A
Romania   Balkan   SPC
Slovenia    Balkan   NAT/SPC
Estonia    Baltic   NAT/SPC
Lithuania     Baltic   NAT/SPC
Latvia     Baltic   NAT/SPC
Czech Republic    Central Europe  NAT/SPC
Hungary    Central Europe  SPC
Poland     Central Europe  SPC
Slovakia     Central Europe  NAT/SPC
Serbia & Montenegro    Central Europe  N/A
Cyprus     Mediterranean  NAT/SPC
Greece     Mediterranean  SPC
Israel     Mediterranean  NAT
Malta     Mediterranean  SPC
Turkey     Mediterranean  N/A
Denmark     Scandinavia  SPC
Finland     Scandinavia  SPC
Iceland     Scandinavia  SPC
Norway     Scandinavia  SPC
Sweden     Scandinavia  SPC
Brazil     South America  N/A
Mexico     South America  N/A
Austria     Western Europe SPC
Belgium     Western Europe  SPC
Switzerland     Western Europe  NAT/SPC
Ireland    Western Europe  SPC
Italy     Western Europe  NAT/SPC
Luxembourg     Western Europe SPC
The Netherlands    Western Europe  SPC
Portugal     Western Europe SPC

Other key information contained in the report:

# Summary of dosage forms, strengths, indications and active ingredient forms of the brand product in major countries**.
# News articles
# Litigation alerts
# Marketing authorisation holders for Great Britain, the United States, Canada and Australia enable you to see who is active in the market.
# US Drug Master Files, providing valuable information to help source active ingredients and keep an eye on competitors.
# Paragraph IV filing; details of US ANDAs filed with a Paragraph IV certification allow easy determination of who the first movers are for a particular generic product in the US.
# 'Patent Risk Analysis' section containing three graphical displays of data drawn from known patent filings to provide valuable competitor insight and development information***.

Key Patent Indicator

The 'Key Patent Indicator' section is intended only to provide an indication of the Key Patents pertaining to a generic drug, and is not based on a comprehensive patent search (a comprehensive patent search can be found in the corresponding Pipeline Selector report).

General Drug Information

Information contained in 'General Indications' and 'Brand Product Attributes' is based on products containing the active pharmaceutical ingredient, which are currently registered in Australia, UK and the USA. Indications are summarised where appropriate and may vary between individual countries.

Patent Risk Analysis

The three graphical analyses are based on data contained in our Pipeline Selector comprehensive patent search, and thus are subject to its scope and limitations. These graphics are intended to provide only a summary of the patent filings; specific details of the filings should be investigated through the use of the Pipeline Selector reports.

Pipeline Selector is just one of the benchmark products from GenericsWeb's Pipeline Patent Intelligence product suite.

Table of Content

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.

• Includes key patent publications for 44 countries
• Contains SPC protection for every EU state plus patent term extensions in other countries
• Data exclusivity calculated on a country by country basis
• Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
• DMF & Paragraph IV filings
• Litigation alerts
• Marketing authorisation holders in selected territories
• Patent risk analysis via graphical display of data from patent filings
• Hyper-linking to crucial patent documents and national registries enabling data verification

List of Tables

List of Figures